ArriVent BioPharma, Inc. AVBP Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense Product With Specified Ingredient by Product | ||||||
| Drug Firmonertinib Favour | $331K+409% | $65K-74.9% | $259K+265% | $71K+3,450% | $2K-98.6% | |
| Drug Firmonertinib Further | $1.74M-23.7% | $2.28M+7.6% | $2.12M-25.7% | $2.85M+9.7% | $2.6M+42.0% | |
| Drug Firmonertinib Furvent | $9.13M-41.8% | $15.69M+13.6% | $13.82M+41.1% | $9.79M+3.7% | $9.45M-4.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ArriVent BioPharma, Inc. break its business down?
- ArriVent BioPharma, Inc. (AVBP) reports research and development expense product with specified ingredient by product across 3 parts — Drug Firmonertinib Favour, Drug Firmonertinib Further and Drug Firmonertinib Furvent. Each is extracted from the segment footnotes and tracked over time.
- Where does ArriVent BioPharma, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ArriVent BioPharma, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.